Last Updated : December 20, 2019
Today, CADTH has issued final recommendations for:
inotersen (Tegsedi)
Indications: hereditary transthyretin amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions
Last Updated : December 20, 2019